Recent LIXT News
- LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial • GlobeNewswire Inc. • 06/14/2024 03:00:00 PM
- LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial • GlobeNewswire Inc. • 06/14/2024 01:30:00 PM
- Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System • GlobeNewswire Inc. • 06/06/2024 12:30:00 PM
- LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer • GlobeNewswire Inc. • 06/03/2024 12:30:00 PM
- LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer” • GlobeNewswire Inc. • 05/08/2024 01:25:00 PM
- Mixed Shelf Filing Gives Micro Cap Delayed Boost • AllPennyStocks.com • 04/24/2024 07:25:00 PM
- Biotech Steals The Show Following Pre-Clinical Data Announcement • AllPennyStocks.com • 03/27/2024 07:35:00 PM
- NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:59:41 PM
- Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 03:48:13 PM
- LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI • GlobeNewswire Inc. • 02/26/2024 01:30:00 PM
- First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial • GlobeNewswire Inc. • 01/29/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 10:21:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 07:28:17 PM
- LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations • GlobeNewswire Inc. • 11/13/2023 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:16:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 09:27:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 06:51:08 PM
- LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration • GlobeNewswire Inc. • 10/16/2023 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/10/2023 07:55:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/10/2023 07:47:19 PM
- LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach • GlobeNewswire Inc. • 10/09/2023 12:30:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 10/06/2023 12:39:03 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM